MeCP2 Optimized for Brain Delivery Holds Promise as Protein Replacement Therapy for RTT, Early Study Suggests
A recombinant version of MeCP2 — the faulty protein in Rett syndrome — has the potential to enter the brain, encouraging its development as a protein replacement therapy for the disease, researchers say. The scientists have also developed an assay that can accurately and sensitively detect MeCP2, which…